previously healthy adults with acute infections such as otitis, sinusitis, pneumonia, or endocarditis. Their article also emphasizes the importance of pneumococcal meningitis as a systemic as well as neurological condition: death in pneumococcal meningitis may result from the central nervous system infection itself, from pneumococcal sepsis with its complications of shock and disseminated intravascular coagulation ± or from a combination of both intracranial and systemic insults. Thus, treatment of the patient with pneumococcal meningitis requires meticulous attention to details of general patient care well beyond that required for treatment of the meningitis itself.
Bacterial meningitis is a complex, rapidly progressive disorder in which neurological injury is caused in part by the causative organism and in part by the host's own in¯amma-tory response. Meningeal S. pneumoniae bacteria do not readily penetrate the pia and invade the brain. However, the interaction between pneumococcus and host results in meningeal in¯ammation, vascular injury, disruption of the blood-brain barrier, vasogenic, interstitial and cytotoxic edema, and disruption of normal CSF¯ow (®gure 1). At the molecular level, S. pneumoniae cell walls have been shown to induce cerebrovascular endothelial cells, microglia, and meningeal in¯ammatory cells to release cytokines, chemokines and reactive oxygen species (Scheld et al., 2002) . These include tumor necrosis factor alpha, interleukins 1 and 6, platelet-activating factor, peroxynitrites, matrix metalloproteinases and urokinase plasminogen activator. Release of cytokines in response to bacterial products is also believed to play a role in the development of disseminated intravascular coagulation in the setting of pneumococcal sepsis. Other components of host response will almost certainly be found to play a role in neurological injury, as well.
Modern antibiotics rapidly sterilize CSF in pneumococcal meningitis within hours to a day of initiation (Kanegaye et al., 2001) . However, many of the neurological and systemic conditions which contribute to morbidity and mortality in pneumococcal meningitis ± in particular vascular injury and cerebral edema ± have already been set into motion by the time antibiotics are begun and are, themselves, not directly responsive to antibiotic therapy. Acute treatment of pneumococcal meningitis with dexamethasone has been found, in both adults (de Gans et al., 2002) and children (McIntyre et al., 1997) , to reduce the incidence of neurological sequelae.
However, its effect is limited, and there is clear need for new adjunctive drugs which are more effective in controlling cerebral in¯ammation and edema. Development of these newer therapies will require greater knowledge of the molecular and pathological events involved in pneumococcal meningitis and a better understanding as to how these events may be interrupted in the patient receiving effective antibiotic therapy. Animal models of bacterial meningitis provide a powerful tool with which to study the sequence of intracranial events involved in meningeal invasion and neurological injury (Koedel and P®ster, 1999) ; and recent studies of experimental bacterial meningitis suggest potential bene®t from several drugs that inhibit CSF cytokines, matrix metalloproteinases and reactive oxygen species. In man, cerebral neuroimaging studies, as shown by Kastenbauer et al., have the potential to monitor the intracranial consequences of meningitis in humans at multiple points in time and could help guide therapy directed at speci®c aspects of the infection.
Ultimate control of pneumococcal meningitis, like elimination of Haemophilus in¯uenzae as a cause of early childhood meningitis, may be brought about by widespread use of effective vaccine. Multiple serotype pneumococcal vaccines are now available for children and high risk adults, but data concerning their ef®cacy in preventing pneumococcal meningitis is limited, and vaccine failures have been reported in asplenic individuals (Peltola, 1999) . Unfortunately, in 2003 the prognosis for patients with S. pneumoniae meningitis remains neither qualitatively nor quantitatively different than it was thirty years ago. While antibiotics are essential, they are insuf®cient and research is needed to develop better adjunctive therapies. Larry E. Davis Neurology Service New Mexico VA Health Care System Albuquerque, NM, USA John E. Greenlee Neurology Service Salt Lake Veterans Affairs Medical Center and Department of Neurology University of Utah School of Medicine Salt Lake City, UT, USA
